RT Journal Article
SR Electronic
T1 Myopic choroidal neovascularisation: current concepts and update on clinical management
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP 289
OP 296
DO 10.1136/bjophthalmol-2014-305131
VO 99
IS 3
A1 Tien Y Wong
A1 Kyoko Ohno-Matsui
A1 Nicolas Leveziel
A1 Frank G Holz
A1 Timothy Y Lai
A1 Hyeong Gon Yu
A1 Paolo Lanzetta
A1 Youxin Chen
A1 Adnan Tufail
YR 2015
UL http://bjo.bmj.com/content/99/3/289.abstract
AB Choroidal neovascularisation (CNV) is a common vision-threatening complication of myopia and pathological myopia. Despite significant advances in understanding the epidemiology, pathogenesis and natural history of myopic CNV, there is no standard definition of myopic CNV and its relationship to axial length and other myopic degenerative changes. Several treatments are available to ophthalmologists, but with the advent of new therapies there is a need for further consensus and clinical management recommendations. Verteporfin photodynamic therapy has been an established treatment for subfoveal myopic CNV for many years, but this treatment does not restore visual acuity and is associated with long-term chorioretinal atrophy. More recently, clinical trials investigating the efficacy and safety of anti-vascular endothelial growth factor agents in patients with myopic CNV have demonstrated substantial visual acuity gains and quality of life increases compared with photodynamic therapy. These enhanced outcomes provide updated evidence-based clinical management guidelines of myopic CNV, and increase the need for a generally accepted definition for myopic CNV. This review critically summarises the latest myopic CNV literature in the context of clinical experience and recommends a myopic CNV treatment algorithm.